These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8213896)

  • 1. Southwestern internal medicine conference: restenosis: the Achilles heel of coronary angioplasty.
    Lange RA; Willard JE; Hillis LD
    Am J Med Sci; 1993 Oct; 306(4):265-75. PubMed ID: 8213896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restenosis after coronary angioplasty for rapidly progressive coronary stenosis.
    Bauters C; Passart F; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
    Eur Heart J; 1996 Nov; 17(11):1671-7. PubMed ID: 8922915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restenosis following coronary angioplasty.
    Fanelli C; Aronoff R
    Am Heart J; 1990 Feb; 119(2 Pt 1):357-68. PubMed ID: 2405612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Foley DP; Rensing BJ; Serruys PW
    Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restenosis rate after multiple percutaneous transluminal coronary angioplasty procedures at the same site. A quantitative angiographic study in consecutive patients undergoing a third angioplasty procedure for a second restenosis.
    Bauters C; Mc Fadden EP; Lablanche JM; Quandalle P; Bertrand ME
    Circulation; 1993 Sep; 88(3):969-74. PubMed ID: 8353924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the different percutaneous revascularization techniques in single and multivessel coronary artery disease.
    Corcos T; Zimarino M; Tamburino C; Favereau X
    Cardiologia; 1993 Dec; 38(12 Suppl 1):383-95. PubMed ID: 8020040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restenosis following coronary angioplasty: clinical presentations and therapeutic options.
    Levine GN; Chodos AP; Loscalzo J
    Clin Cardiol; 1995 Dec; 18(12):693-703. PubMed ID: 8608668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study.
    Miner SE; Hegele RA; Sparkes J; Teitel JM; Bowman KA; Connelly PW; Banijamali H; Lau HK; Chisholm RJ; Babaei S; Strauss BH
    Am Heart J; 2000 Aug; 140(2):272-8. PubMed ID: 10925342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restenosis after percutaneous transluminal coronary angioplasty.
    Kent KM
    Am J Cardiol; 1988 May; 61(14):67G-70G. PubMed ID: 2966567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target?
    Currier JW; Faxon DP
    J Am Coll Cardiol; 1995 Feb; 25(2):516-20. PubMed ID: 7829808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty.
    Take S; Matsutani M; Ueda H; Hamaguchi H; Konishi H; Baba Y; Kawaratani H; Sugiura T; Iwasaka T; Inada M
    Am J Cardiol; 1997 Apr; 79(8):1097-9. PubMed ID: 9114771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restenosis, the Achilles' heel of coronary angioplasty.
    Wurdeman RL; Hilleman DE; Mooss AN
    Pharmacotherapy; 1998; 18(5):1024-40. PubMed ID: 9758313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restenosis after percutaneous transluminal coronary angioplasty.
    Foley DP; Hermans WM; Rensing BJ; de Feyter PJ; Serruys PW
    Herz; 1992 Feb; 17(1):1-17. PubMed ID: 1541446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ischemia: reperfusion injury and restenosis after coronary angioplasty.
    Park JW; Braun P; Mertens S; Heinrich KW
    Ann N Y Acad Sci; 1992 Sep; 669():215-36. PubMed ID: 1444028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
    J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group.
    Faxon DP
    J Am Coll Cardiol; 1995 Feb; 25(2):362-9. PubMed ID: 7829789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised trial of elective stenting after successful percutaneous transluminal coronary angioplasty of occluded coronary arteries.
    Hancock J; Thomas MR; Holmberg S; Wainwright RJ; Jewitt DE
    Heart; 1998 Jan; 79(1):18-23. PubMed ID: 9505913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.